David Bredt

David Bredt appears in our data through filings on Rapport Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 14 March 2025 to 17 February 2026, the count stands at 13 filings.

No open-market purchase appears, only 12 sales worth €1.3M. Outside the open market, there are 1 share grant. In 2026 alone, the filings show no purchases and 2 sales.

On 19 February 2026 came the latest disclosure, an open-market sale for €21k in Rapport Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.